Posted by Michael Wonder on 08 Sep 2021
HiberCell receives fast track designation from FDA for first in human studies of PERK inhibitor (PERKi) HC-5404-FU
8 September 2021 - C-5404-FU PERKi program is currently in a Phase 1a clinical trial for the treatment of solid tumours.
HiberCell announced today that the U.S. FDA has granted the company fast track designation for HC-5404-FU, an orally administered PERK inhibitor for patients with solid tumours.
